LNTH.OQ
Latest Trade
16.57USDChange
0.00(0.00%)Volume
209,891Today's Range
-
16.6052 Week Range
-
29.80As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 16.57 |
|---|---|
Open | 16.39 |
Volume | 209,891 |
3M AVG Volume | 7.41 |
Today's High | 16.60 |
Today's Low | 16.22 |
52 Week High | 29.80 |
52 Week Low | 16.10 |
Shares Out (MIL) | 39.25 |
Market Cap (MIL) | 650.34 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Lantheus Announces Topline Results For BENEFIT 1 LVEF Clinical Trial
Progenics Pharmaceuticals Provides Update On Reconstituted Board's Ongoing Strategic Review
Lantheus Enters Into Strategic Collaboration With Carthera For Use Of Microbubbles In Combination With Sonocloud System For Treatment Of Glioblastoma
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.
Executive Leadership
Brian A. Markison
Non-Executive Independent Chairman of the board
Mary Anne Heino
President, Chief Executive Officer, Director
Robert J. Marshall
Chief Financial Officer, Treasurer
John J Bolla
Chief Operating Officer, Senior Vice President, Technical Operations
Michael P. Duffy
Senior Vice President, Law and Public Policy, General Counsel and Secretary
Price To Earnings (TTM) | 19.14 |
|---|---|
Price To Sales (TTM) | 1.89 |
Price To Book (MRQ) | 6.43 |
Price To Cash Flow (TTM) | 13.62 |
Total Debt To Equity (MRQ) | 194.27 |
LT Debt To Equity (MRQ) | 184.22 |
Return on Investment (TTM) | 9.68 |
Return on Equity (TTM) | 8.34 |
* LANTHEUS HOLDINGS - PROGENICS SHAREHOLDERS WILL RECEIVE 0.31 SHARES OF LANTHEUS COMMON STOCK FOR EACH SHARE OF PROGENICS STOCK IN ALL-STOCK DEAL
* Q1 EARNINGS PER SHARE VIEW $0.22 -- THOMSON REUTERS I/B/E/S
* LANTHEUS HOLDINGS APPOINTS GARY PRUDEN, KENNETH PUCEL AND DR. JAMES THRALL TO ITS BOARD OF DIRECTORS
* LANTHEUS HOLDINGS, INC. REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE
* LANTHEUS HOLDINGS-ON DEC. 30, 2017, LANTHEUS MEDICAL ENTERED BINDING EXTENSION OF SUPPLY AGREEMENT WITH JUBILANT DRAX IMAGES,EFFECTIVE JAN. 1, 2018
* Lantheus Holdings Inc reports 2017 third quarter financial results; exceeds third quarter and raises full-year 2017 guidance
* Lantheus Holdings, Inc. reports 2017 second quarter financial results; exceeds second quarter and raises full-year 2017 guidance
* Lantheus Holdings, Inc. Reports 2017 first quarter financial results; exceeds first quarter and raises full-year 2017 guidance
* Lantheus Holdings Inc says closing of a new $275 million term loan facility and a new $75 million five-year cash-flow revolver facility
* Reports 2016 fourth quarter and full year financial results; provides 2017 guidance
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.